Journal of obstetrics and gynaecology Canada最新文献

{"title":"Corrigendum to ‘Discovering the Hidden Curriculum in Postgraduate Medical Education: A Scoping Review’ [J Obstet Gynaecol Can. 46 (2024) 102495]","authors":"Virginia Goetz, Christa Aubrey, Jennifer Gelfand, Kaylie Welykholowa","doi":"10.1016/j.jogc.2024.102754","DOIUrl":"10.1016/j.jogc.2024.102754","url":null,"abstract":"","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"47 2","pages":"Article 102754"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal Colonization of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Preterm Rupture of Membranes","authors":"Inshirah Sgayer MD ,&nbsp;Muhammad Zidan MD ,&nbsp;Yara Nakhleh Francis MD ,&nbsp;Raneen Abu Shqara MD ,&nbsp;Daniel Glikman MD ,&nbsp;Lior Lowenstein MD ,&nbsp;Maya Frank Wolf MD","doi":"10.1016/j.jogc.2024.102755","DOIUrl":"10.1016/j.jogc.2024.102755","url":null,"abstract":"<div><h3>Objectives</h3><div>Maternal colonization by extended-spectrum β-lactamase-producing <em>Enterobacteriaceae</em> (ESBL-E) has risen, and the antimicrobial resistance of ESBL-E is significant. We aimed to evaluate the rates of ESBL-E colonization among women with preterm premature rupture of membranes (PPROM) and of maternal-neonatal vertical transmission. We also aimed to compare obstetrical and neonatal complications among ESBL-E positive versus negative maternal colonization in pregnancies complicated by PPROM.</div></div><div><h3>Methods</h3><div>This retrospective study included women with PPROM who were admitted from 2018 to 2022 for expectant management and were screened for ESBL-E recto-vaginal colonization on their admission. Obstetrical and neonatal outcomes were compared between positive and negative ESBL-E pregnancies. Neonatal outcomes were compared between positive and negative ESBL-E neonates.</div></div><div><h3>Results</h3><div>Of 118 women with PPROM, 27 (23%) had positive ESBL-E cultures. ESBL-E isolates (cultures from the placenta, cord, amnion, or uterus) were more common in colonized versus non-colonized ESBL-E mothers (55.6% vs. 11.0%, <em>P</em> &lt; 0.001). ESBL-E isolates were more common in neonates of mothers with positive versus negative ESBL-E cultures (33.3% vs. 4.2%, <em>P</em> = 0.017). A higher proportion of neonates of ESBL-E positive than ESBL-E negative mothers needed antibiotic treatment in the neonatal intensive care unit. Neonatal ESBL-E colonization at birth was a predictor of longer stays in the neonatal intensive care unit (<em>P</em> = 0.006).</div></div><div><h3>Conclusions</h3><div>In women with PPROM<strong>,</strong> maternal–ESBL-E colonization was a significant risk factor for neonatal colonization and was associated with neonatal morbidity. The high maternal colonization rate in PPROM raises the need for routine maternal ESBL screening. Future studies should establish the ideal empiric antibiotic regimen in the neonatal intensive care unit for neonates born to ESBL-E colonized mothers.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"47 2","pages":"Article 102755"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-Trimester PlGF and PAPP-A and the Risk of Placenta-Mediated Complications: PREDICTION Prospective Study","authors":"Marie-Laurence Côté MD ,&nbsp;Yves Giguère MD, PhD ,&nbsp;Jean-Claude Forest MD, PhD ,&nbsp;Francois Audibert MD, MSc ,&nbsp;Jo Ann Johnson MD ,&nbsp;Nan Okun MD ,&nbsp;Paul Guerby MD, PhD ,&nbsp;Louise Ghesquiere MD, PhD ,&nbsp;Emmanuel Bujold MD, MSc","doi":"10.1016/j.jogc.2024.102732","DOIUrl":"10.1016/j.jogc.2024.102732","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to estimate the association between low first-trimester maternal serum PlGF (placental growth factor) and PAPP-A (pregnancy-associated plasma protein A) and the risk of placenta-mediated complications.</div></div><div><h3>Methods</h3><div>We performed a secondary analysis of the PREDICTION study, including nulliparous participants recruited at 11 to 14 weeks of pregnancy. First-trimester PlGF and PAPP-A levels were reported in multiples of the median (MoM) adjusted for maternal characteristics and gestational age. Participants were stratified into 4 groups based on absence/presence of low (&lt;0.4 MoM) PlGF and PAPP-A values. A composite of adverse pregnancy outcomes (including preeclampsia, fetal growth restriction, fetal death, and placental abruption) was calculated for deliveries occurring before 34 weeks, before 37 weeks, and at or after 37 weeks.</div></div><div><h3>Results</h3><div>Out of the 7262 participants, 86 (1.2%) experienced the composite outcome before 37 weeks of gestation, including 35 (0.4%) before 34 weeks. The combination of low PAPP-A and low PlGF levels was associated with the greatest risk of adverse outcomes before 37 weeks (21%) and before 34 weeks (12%) compared with low PlGF alone (7% and 3%), low PAPP-A alone (2% and 1%), or neither marker (1% and 0.4%, respectively; <em>P</em> &lt; 0.001). For preterm preeclampsia specifically, the combination of low PAPP-A and low PlGF was also associated with a greater risk (12%) compared with low PlGF alone (6%), low PAPP-A alone (0.5%), or neither marker (0.7%; <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The combination of low PAPP-A and low PlGF levels is associated with a very high risk for adverse outcomes before 34 and 37 weeks. An isolated low PAPP-A should not be considered a risk factor for adverse pregnancy outcomes.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"47 2","pages":"Article 102732"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unique Findings in Placenta Accreta Following Adenomyomectomy","authors":"Shunya Sugai MD,&nbsp;Kazufumi Haino MD, PhD,&nbsp;Kosuke Yoshihara MD, PhD,&nbsp;Koji Nishijima MD, PhD","doi":"10.1016/j.jogc.2024.102750","DOIUrl":"10.1016/j.jogc.2024.102750","url":null,"abstract":"","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"47 2","pages":"Article 102750"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction Model for Cesarean Scar Disorder Disappearance After Transvaginal Uterine Diverticulum Repair","authors":"Qing Yang MS ,&nbsp;Xiaoli Lv MS ,&nbsp;Wenjing Wang MS ,&nbsp;Fenghua Chen BD ,&nbsp;Liping Yao PhD ,&nbsp;Min Ren PhD","doi":"10.1016/j.jogc.2024.102736","DOIUrl":"10.1016/j.jogc.2024.102736","url":null,"abstract":"<div><h3>Objectives</h3><div>Cesarean scar disorder (CSD) is a recently defined condition resulting from cesarean delivery (CD) surgery, and transvaginal uterine diverticulum repair (TVUDR) is generally chosen for treatment of CSD. This study constructed a prediction model for CSD disappearance after TVUDR using imaging data for CSD measured by transvaginal ultrasound (TVU), MRI, and contrast-enhanced MRI.</div></div><div><h3>Methods</h3><div>The data of 283 women with previous CD treated with TVUDR were retrospectively collected between January 2014 and February 2016. The imaging data for the CSD parameters were measured, including length, width (W), depth (D), residual myometrium thickness (RMT), RMT/depth (RMT/D)<em>,</em> and RMT/(RMT + depth) [RMT/(RMT+D)].</div></div><div><h3>Results</h3><div>Of the patients included, 129 women presented with disappearance of CSD. We noted potential differences between CSD disappearance and existence after TVUDR for W, RMT, RMT/D, and RMT/(RMT+D) measured by MRI, and D, RMT/D, and RMT/(RMT+D) measured by contrast-enhanced MRI. After adjusting for potential confounding factors, W measured using MRI was found to be associated with the disappearance of CSD (OR 1.134; 95% CI 1.050–1.224, <em>P</em> = 0.001). Subsequently, the W measured by MRI was selected in the prediction model, for which the C-index was 0.624. The area under the receiver operating characteristic curve in the least absolute shrinkage and selection model was 62.40% (95% CI 54.96–69.83%).</div></div><div><h3>Conclusions</h3><div>MRI and contrast-enhanced MRI were found to be relatively accurate methods for detecting CSD. Moreover, W measured using MRI was significantly associated with the disappearance of CSD after TVUDR.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"47 2","pages":"Article 102736"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-Trimester Soluble fms-like Tyrosine Kinase 1 (sFlt-1) for the Prediction of Preterm Preeclampsia","authors":"Alexandre Fillion MD, MSc ,&nbsp;Amélie Boutin PhD ,&nbsp;Yves Giguère MD, PhD ,&nbsp;Jean-Claude Forest MD, PhD ,&nbsp;Louise Ghesquière MD, PhD ,&nbsp;Emmanuel Bujold MD, MSc","doi":"10.1016/j.jogc.2024.102753","DOIUrl":"10.1016/j.jogc.2024.102753","url":null,"abstract":"<div><div>While soluble fms-like tyrosine kinase 1 (sFlt-1) is used to predict preeclampsia (PE) and its severity in late pregnancy, we aimed to clarify its role in early pregnancy. Using prospective cohorts, we estimated the association between sFlt-1, adjusted for gestational age, and preterm PE. sFlt-1 was significantly decreased in the first trimester, mostly before the 13th week, and significantly increased in the third trimester in those who developed preterm PE and particularly early-onset PE. We hypothesize that sFlt-1 evolves from low to high values in early to late pregnancy among women with preterm and early-onset PE.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"47 2","pages":"Article 102753"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Déclaration de consensus clinique N° 458 : Le virus de l'hépatite C pendant la grossesse","authors":"Andrea Atkinson MBBS,&nbsp;Natalie Bjurman MD,&nbsp;Mark Yudin MD,&nbsp;Chelsea Elwood MD","doi":"10.1016/j.jogc.2025.102781","DOIUrl":"10.1016/j.jogc.2025.102781","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Fournir des orientations pour le dépistage prénatal systématique du virus de l'hépatite C pendant la grossesse afin de soutenir les meilleures pratiques et d'optimiser les soins prénataux et les soins liés aux maladies infectieuses.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Population cible&lt;/h3&gt;&lt;div&gt;Les femmes enceintes et les personnes enceintes bénéficiant de soins prénataux au Canada et consentant à un dépistage systématique des maladies infectieuses. Les options comprennent l'examen des sérologies antérieures et l'évitement d'un nouveau test ou la fourniture d'informations sur les avantages de l'identification de l'infection par le virus de l'hépatite C pour la mère/le parent et le bébé.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Avantages, inconvénients et coûts&lt;/h3&gt;&lt;div&gt;Les avantages peuvent inclure l'identification des personnes éligibles au traitement de l'infection par le virus de l'hépatite C, l'évitement d'interventions susceptibles d'augmenter le risque de transmission au bébé pendant le travail et l'accouchement, la création d'opportunités pour un dépistage approprié des nouveau-nés et la réduction du fardeau de l'infection par le virus de l'hépatite C conformément aux recommandations de l'Organisation mondiale de la santé. Il n'y a pas d'inconvénients directs étant donné la possibilité de tester l'hépatite C à l'aide des échantillons de sang déjà inclus dans le dépistage prénatal. Un nouveau diagnostic du virus de l'hépatite C pendant la grossesse peut entraîner une détresse psychologique. Le coût de l'identification des cas asymptomatiques, avec le traitement qui en découle, est supérieur au coût des soins de santé de ce test supplémentaire.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Données probantes&lt;/h3&gt;&lt;div&gt;La littérature publiée et non publiée a été examinée entre 2017 et juillet 2023 (date de la dernière approbation de la précédente ligne directrice sur l'hépatite C, No. 96 The Reproductive care of Women Living with Hepatitis C infection) : No. 96 The Reproductive care of Women Living with Hepatitis C infection, a été approuvée pour la dernière fois). Les bases de données OVID Medline, Embase, PubMed et la Cochrane Library ont été consultées pour trouver les publications pertinentes disponibles en anglais pour chaque section de cette déclaration. La littérature non publiée, les protocoles et les lignes directrices internationales ont été identifiés en accédant aux sites web des agences liées à la santé, aux collections de lignes directrices de pratique clinique et aux sociétés nationales et internationales de spécialité médicale (c'est-à-dire l'American College of Obstetricians and Gynecologists, le Royal College of Obstetricians and Gynaecologists et le Royal Australian and New Zealand College of Obstetricians and Gynaecologists).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes de validation&lt;/h3&gt;&lt;div&gt;Les données probantes ont été obtenues et examinées par les auteurs principaux, et les recommandations ont été examinées par le Comité des maladies infectieuses de la SOGC (2022). Les aut","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"47 2","pages":"Article 102781"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143479110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Are the Current HPV Types Contributing to Cervical High-Grade Squamous Intraepithelial Lesions, Adenocarcinoma In Situ, and Early Cervical Cancer?","authors":"Lina Salman MD, MSc ,&nbsp;Lilian T. Gien MD, MSc ,&nbsp;Danielle Vicus MD, MSc ,&nbsp;Michael Shier MD ,&nbsp;Rachel Kupets MD ,&nbsp;Suzanne Gibbons BSc ,&nbsp;Samar Ashfaq BSc ,&nbsp;Alberto Severini MD ,&nbsp;Allan Covens MD","doi":"10.1016/j.jogc.2025.102783","DOIUrl":"10.1016/j.jogc.2025.102783","url":null,"abstract":"<div><h3>Objectives</h3><div>To determine the prevalence of human papillomavirus (HPV) types by genotyping high-grade squamous intraepithelial lesion (HSIL), adenocarcinoma in situ (AIS), and early-stage invasive cervical cancer (ICC) in patients who have been exposed or are naïve to the HPV vaccine.</div></div><div><h3>Methods</h3><div>This was a cross-sectional study. All patients over the age of 18 years who presented to the colposcopy clinic with HSIL, AIS, or ICC who were expected to undergo a cervical biopsy, loop electrosurgical excisional procedure, or cone biopsy were eligible and approached for informed consent. HPV typing was performed to identify the causative HPV types.</div></div><div><h3>Results</h3><div>Between November 2016 and May 2023, 113 patients (34 vaccinated with at least 1 dose, and 79 non-vaccinated) consented to this study. The median ages at coitarche and study entry were 18 (range 14–37) and 34 (range 24–66) years, respectively. Only 3 patients were vaccinated prior to coitarche.</div><div>Histology was as follows: HSIL = 97, AIS = 9, HSIL and AIS = 2, squamous cell carcinoma = 4, and 1 patient with adenocarcinoma. The causative HPV type was 16 or 18 in 59% of the vaccinated group and in 66% of the non-vaccinated group. Most vaccinated patients (74%) reported receiving 2–3 doses of HPV vaccine.</div></div><div><h3>Conclusions</h3><div>In our cohort, the distribution of causative HPV 16 and 18 in patients presenting with HSIL/AIS/ICC was similar between vaccine-naïve and vaccinated patients. This data suggests cervical screening guidelines should not differentiate between “vaccinated” and “non-vaccinated” women without further details of their vaccination.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"47 3","pages":"Article 102783"},"PeriodicalIF":2.0,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143083094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoxic respiratory failure in metastatic low grade serous ovarian cancer – a rare newly diagnosed patent foramen ovale","authors":"Samantha Taylor MD ,&nbsp;Shuk On Annie Leung MD ,&nbsp;Gabriel Levin MD","doi":"10.1016/j.jogc.2025.102782","DOIUrl":"10.1016/j.jogc.2025.102782","url":null,"abstract":"","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"47 3","pages":"Article 102782"},"PeriodicalIF":2.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"sFlt-1, Coagulation Function, and Platelets as Predictors of Preeclampsia","authors":"Jiani Yuan MM,&nbsp;Duanqing Wu BM,&nbsp;Jun Ye MM,&nbsp;Rujun Chen MM,&nbsp;Xiaoqin Wang MM,&nbsp;Liwen Zhang BM","doi":"10.1016/j.jogc.2025.102772","DOIUrl":"10.1016/j.jogc.2025.102772","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the predictive value of soluble FMS-like tyrosine kinase-1 (sFlt-1), coagulation function, and platelet (PLT) parameters for preeclampsia (PE).</div></div><div><h3>Methods</h3><div>A prospective study was conducted on women registered and delivered at Shanghai Fifth People's Hospital from October 2020 to December 2021. All eligible pregnant women were recruited at the time of initial registration in the first trimester. We then obtained serum samples uniformly at 24⁰–28⁰ weeks and stored these samples in a freezer at −80°C and labelled them to create a biobank. Later, when PE was diagnosed, we followed the markers to find their blood samples and complete the tests. Participants were divided into healthy pregnant (HP) and PE groups. Participants were divided into HP and PE groups. Approximately 5 mL of venous blood was collected from each participant at 24⁰–28⁰ weeks gestation. Serum sFlt-1 was measured by enzyme-linked immunosorbent assay. Additionally, D-dimer, activated partial thromboplastin time (APTT), thrombin time (TT), prothrombin time (PT), antithrombin III (ATIII), fibrinogen, PLT, PLT distribution width (PDW), and mean PLT volume (MPV) were recorded. SPSS 27.0 software was used to analyze the correlation of these parameters with PE. Receiver operating characteristic curve analysis determined the optimal cutoff value for each parameter.</div></div><div><h3>Results</h3><div>Serum sFlt-1, APTT, TT, ATIII, PLT, MPV, and PDW levels were significantly different between the PE and HP groups (<em>P</em> &lt; 0.05). Among single-factor indicators for predicting PE, sFlt-1 exhibited the highest value. With an optimal cutoff value of 4.409 ng/mL, sFlt-1 demonstrated a sensitivity and specificity of 85.4% and 87.5%, respectively. The combination of sFlt-1, APTT, TT, PDW, and MPV yielded the highest predictive value, with an area under the receiver operating characteristic curve of 0.946, sensitivity of 86.8%, and specificity of 87.5%.</div></div><div><h3>Conclusions</h3><div>This study demonstrates that a combination of sFlt-1, APTT, TT, PDW, and MPV is a valuable tool for predicting PE.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":"47 3","pages":"Article 102772"},"PeriodicalIF":2.0,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}